Loading
Life sciences · Journal article
Small · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT The facile construction of high‐performance photothermal nanozymes that simultaneously possess hollow architectures and heterojunction structures is highly appealing for tumor therapy. Herein, sulfur‐mediated hollow engineering was used to fabricate S‐FeSe 2 /CuCoSe 2 heterojunction nanozymes via one‐step hydrothermal synthesis, with uniform ∼ 200 nm hollow cubic morphology and homogeneous elemental distribution. S‐doping and the hollow heterojunction structure of S‐FeSe 2 /CuCoSe 2 endow the nanozyme with excellent photothermal conversion efficiency (PCE) at NIR‐II regime (1064 nm), which reaches as high as 56.1%, in contrast to 33.7% for pristine FeSe 2 /CuCoSe 2. S‐FeSe 2 /CuCoSe 2 nanozymes also show better performance in peroxidase (POD)‐like activity ( K m = 0.28 mM, V max = 43.8 nM/s) than FeSe 2 /CuCoSe 2 ( K m = 0.54 mM, V max = 27.3 nM/s). Meanwhile, its oxidase (OXD)‐ and glutathione peroxidase (GPx)‐like activities are significantly enhanced. In vitro, S‐FeSe 2 /CuCoSe 2 showed low cytotoxicity to normal cells and induced 75.4% apoptosis of 4T1 cells under laser irradiation via ROS burst and mitochondrial damage. In vivo 4T1 tumor models confirmed efficient synergistic photothermal/enzymatic therapy with significant tumor inhibition and bare toxicity. This work offers a novel strategy for designing high‐performance heterojunction nanozymes for cancer therapy.